

The role of urinary fractionated metanephrines in the diagnosis of pheochromocytoma

Kanakamani Jeyaraman, Vasanthi Natarajan, Nihal Thomas, Paul Mazhuvanchary Jacob*, Aravindan Nair*, Nylla Shanthly**, Regi Oommen**, Gracy Varghese⁺, Fleming Jude Joseph⁺, Mandalam Subramaniam Seshadri & Simon Rajaratnam

*Departments of Endocrinology, *Endocrine Surgery, **Nuclear Medicine & ⁺Clinical Biochemistry, Christian Medical College, Vellore, India*

Received April 18, 2011

Background & objectives: Plasma and urinary metanephrines are used as screening tests for the diagnosis of pheochromocytoma. The recommended cut-off levels are not standardized. This study was conducted to identify a cut-off level for 24 h urinary fractionated metanephrines *viz.* metanephrine (uMN) and normetanephrine (uNMN) using enzyme immunoassay for the diagnosis of pheochromocytoma.

Methods: Consecutive patients suspected to have pheochromocytoma were included in the study. uMN and uNMN in 24 h urinary sample were measured using a commercial ELISA kit.

Results: Overall, 72 patients were included over a period of 18 months. Twenty patients had histopathologically confirmed pheochromocytoma and in 52 patients pheochromocytoma was ruled out. Using the upper limit of normal stated by the assay manufacturer as the cut-off, uMN >350 µg/day had a low sensitivity and uNMN >600 µg/day had a poor specificity. By increasing the cut-off value of uNMN to twice the upper limit, specificity increased significantly without much loss in sensitivity. Combining uMN and uNMN using a cut-off twice the upper limit improved the diagnostic performance - sensitivity (95%); specificity (92.3%); positive predictive value (PPV - 82.6%); negative predictive value (NPV - 98%). In subsets of patients with a variable pretest probability for pheochromocytoma, the PPV correlates well with the occurred of these tumors decreased, while the NPV remained at 100 per cent.

Interpretation & conclusions: ELISA is a simple and reliable method for measuring uMN and uNMN. The test has a good NPV and can be used as an initial screening test for ruling out pheochromocytoma. Each hospital will have to define the cut-off value for the assay being used, choosing a proper control population.

Key words Adrenal tumour - catecholamines - ELISA - metanephrines - pheochromocytoma

Screening for phaeochromocytoma is an essential part of the aetiological workup for secondary hypertension. Traditionally, urinary vanillyl mandelic acid (VMA) was used to diagnose phaeochromocytoma. However, it has a low sensitivity (60-70%)¹. Later, catecholamines measurement in plasma (PCAT) and urine (UCAT) emerged as useful tests. The sensitivity of catecholamines test is limited by their episodic release from the tumour cells. The reported sensitivity ranges from 76-82 per cent for PCAT and 71-86 per cent for UCAT. The specificity ranges from 81-100 per cent for PCAT and 88-99 per cent for UCAT².

Metanephrines are ortho-methylated metabolites of catecholamines. These are secreted continuously from the tumour cells, independent of the intermittent release of catecholamines³. The metanephrines are later metabolized by conjugation, primarily in the hepatomesentric organs⁴. Plasma metanephrines (pMN) are measured in the free form whereas urinary metanephrines (uMN) represent predominantly the conjugated form. Hence compared to pMN, uMN is less specific. Studies have proved that plasma free metanephrines have a sensitivity of 96-100 per cent and specificity of 85-100 per cent superior to that of uMN which has a sensitivity of 93-99.6 per cent and specificity of 71-77 per cent⁵.

Previous, methods using colorimetry or spectrophotometry as total MET (metanephrine + normetanephrines) which includes a combined measurement of metanephrine (MN) and normetanephrine (NMN). These methods were superseded by liquid chromatographic assays (LC) that allow individual measurement of MN and NMN. The cost involved and the need for special instruments like mass spectrometry (MS) for such assays preclude their routine clinical use. Immunoassays are now available for the measurement of metanephrines and a few studies have shown that the enzyme immunoassay compares well with HPLC measurement and is a viable alternative to HPLC assays⁶⁻⁸. These assays are relatively simple and are readily available in most clinical laboratories⁹. There is no general agreement regarding the cut-off level of urinary metanephrines for the diagnosis of phaeochromocytoma. The commonly used cut-off levels are from individual institutions which use highly sensitive HPLC assays¹⁰. The aim of the present study was to establish thresholds for urinary metanephrine (uMN) and normetanephrine (uNMN) with optimal sensitivity and specificity for the diagnosis of phaeochromocytoma, using a commercially available enzyme immunoassay.

Material & Methods

Subjects: This study was performed from June 2008 to February 2010 in the Department of Endocrinology, Diabetes & Metabolism, Christian Medical College, Vellore, Tamil Nadu. Consecutive patients attending the outpatient clinic who were suspected to have a phaeochromocytoma, were included in the study. The clinical criteria for suspecting phaeochromocytoma were (i) referral as phaeochromocytoma or, (ii) age at onset of hypertension <40 yr or, (iii) paroxysmal symptoms or, (iv) resistant hypertension or, (v) adrenal mass with or without hypertension. All patients underwent 24 h urine collection for estimation of uMN and uNMN. Phaeochromocytoma was ruled out if imaging (ultrasonography/computed tomography of the abdomen and MIBG meta-idobenzylguanidine scintigraphy) was negative or if the surgically resected adrenal mass was not a phaeochromocytoma. The gold standard for confirmation of phaeochromocytoma was histopathology. All these patients were seen in a multidisciplinary clinic involving endocrinologists, nuclear medicine specialists and endocrine surgeons. Histopathology was examined by a single pathologist.

Sample collection and assay: Patients collected 24 h urine sample in containers with 15 ml of 6 M HCl, as a preservative. The volumes were measured and five ml of the urine sample was stored at -20°C until assayed. uMN and uNMN were analysed using a competitive enzyme immune assay with a commercial ELISA kit (LDN GmbH & Co. KG, Nordhorn) using microtiter plates. The analytical sensitivity of the assay specified by the manufacturer was five ng/ml for MN and 13 ng/ml for NMN. The cross reactivity of substances with similar chemical structure like catecholamines, dopamine and VMA was <0.1 per cent. Control, supplied by the manufacturer was run for each assay. The coefficients of variation for metanephrine at 100 ng/ml was 13.3 per cent and 300 ng/ml was 12.3 per cent; normetanephrine at 300 ng/ml was 12.6 per cent and 800 ng/ml was 11.5 per cent. The normal values as stated by the manufacturer were - uMN <350 µg/day and uNMN < 600 µg/day.

Statistical analysis: The quantitative data are expressed as mean ± SD or median (range). To compare the continuous variables between two independent groups which were normally distributed, the two sample *t* test was used and for skewed distribution, the Mann-Whitney *U* test was used. Sensitivity and specificity of the upper limit were calculated as given by the manufacturer. However, the reference range given by

the manufacturer was based on normal ranges derived from normotensive volunteers which is known to result in excessive false positive testing. From previous studies, it is understood that the 95th percentiles in individuals being tested for pheochromocytoma as part of routine clinical practice (but who do not have the neoplasm) are approximately 50-70 per cent higher than those of normal volunteers¹⁰. Hence, the general recommendation is to consider a positive test to be a two-fold elevation above the upper limit of normal. So twice the upper limit of reference range was considered as a diagnostic cut-off. ROC (receiver operating characteristics) curves were constructed and the areas under the ROC curves (AUC_{ROC}) were calculated. The curves were employed to identify optimal diagnostic thresholds. Statistical analyses were performed with the commercially available software package (SPSS for Windows, version 10.0, SPSS, Inc., Chicago, IL). $P < 0.05$ was considered statistically significant.

Results

Of the 72 patients (52 men and 20 women), nine were referred as pheochromocytoma patients, two were on follow up for metastatic pheochromocytoma and one patient had von Hippel Lindau disease. These 12 patients had histopathologically confirmed pheochromocytomas. In the remaining 60 patients pheochromocytoma screening was done for the following reasons: young hypertensives (n=18), resistant hypertension (n=11), hypertension with paroxysmal symptoms (n=16), adrenal mass with hypertension (n=11) and adrenal mass without hypertension (n=4). Among the 45 patients who presented with hypertension, four were diagnosed to have pheochromocytoma. The remaining 41 hypertensive patients with normal biochemistry, sonographically normal kidneys and renal arteries, negative abdominal imaging and negative MIBG were labelled as essential hypertension (EH). Among 15 patients who had adrenal masses, four with hypertension had histopathologically confirmed pheochromocytoma. In the pheochromocytoma group, 16 had adrenal tumours and four had extra-adrenal tumours. Patients with other types of adrenal masses (n=11) and with EH (n=41) formed the no-pheochromocytoma group.

Clinical profile: The mean age of patients with pheochromocytoma was not statistically different from that of the no-pheochromocytoma group. There was a male preponderance in both groups. Patients with EH had a significantly higher BMI compared

to the patients with pheochromocytoma. The uMN levels were 3.5 fold ($P=0.005$) and uNMN levels were 6.5 fold higher ($P < 0.005$) in the pheochromocytoma group compared to no-pheochromocytoma group. It was observed that extra-adrenal pheochromocytomas had significantly higher uNMN levels compared to those with adrenal pheochromocytomas ($P < 0.05$). The uMN level was not different from that of the no-pheochromocytoma group.

Cut-off for diagnosis of pheochromocytoma: Using the assay manufacturer's upper limit of normal for uMN $>350 \mu\text{g/day}$, 11 of the 20 patients with pheochromocytoma were missed (sensitivity of 45%) but the false positive rate was low (specificity of 92.3%). If the cut-off value was increased to twice the upper limit *i.e.* $>700 \mu\text{g/day}$, there were no false positives but the sensitivity dropped to 35 per cent (Fig.1). No cut-off with better sensitivity and specificity was identified by ROC curve. Similarly, the sensitivity and specificity for uNMN using manufacturer's upper limit of normal $>600 \mu\text{g/day}$ was 90 and 32.7 per cent, respectively. Increasing the cut-off to twice this upper limit *i.e.* $>1200 \mu\text{g/day}$, increased the specificity to 92.3 per cent with some loss in sensitivity to 80 per cent (Fig. 1). The AUC_{ROC} for uMN was 0.722 (0.579-0.864) and for uNMN was 0.870 (0.748-0.992). Using the ROC curve (Fig. 2), a cut-off value of 2794 $\mu\text{g/day}$ resulted in 100 per cent specificity without further decrease in sensitivity.




Fig. 1. Cut-off values for 24 h urinary metanephrine (μMN) and normetanephrine (μNMN) in $\mu\text{g/day}$. The dotted lines represent the cut-off values defined by the upper limit of normal as stated by the assay manufacturer and the broken lines twice the upper limit. In the pheochromocytoma group, circles (O) and triangles (Δ), adrenal and extra-adrenal tumour, respectively. (\square), urinary normetanephrine levels in controls. (\blacksquare), urinary metanephrine levels in controls.




Fig. 2. ROC curve for the 24 h urinary metanephrine (uMN), normetanephrine (μ NMN) and a combination of both (μ MN+ μ NMN).

When uMN and uNMN (uMN+uNMN) were combined *i.e.* uMN > 700 μ g/day and/or uNMN >1200 μ g/day, the sensitivity improved to 95 per cent and specificity to 92.3 per cent. The positive (PPV) and negative predictive values (NPV) were 82.6 and 98 per cent, respectively. The AUC_{ROC} was 0.937 (0.867-1.006) which was better than that of uMN and uNMN separately (Fig. 2). Table II summarises the performance characteristics of the test using different cut-off values for either or both parameters. We divided our study population into four subsets depending on their pretest probability of diagnosing pheochromocytoma. For each of these subsets, we calculated the proportion

of subjects who were finally confirmed to have pheochromocytoma. We then calculated the predictive values of uMN + uNMN in each of these subsets. In the group of patients presenting with hypertension alone, where the pretest probability is low and the occurrence of pheochromocytoma was 8 per cent (the PPV was very low). In those with adrenal mass and hypertension, where the pretest probability is high and the occurrence of pheochromocytoma was high (the PPV was 100%). Table III shows the predictive values of uMN + uNMN in these different clinical settings.

Discussion

Our observation that the uMN+uNMN test has a good sensitivity in the initial screening of a patient with suspected pheochromocytoma is consistent with previous studies¹⁰⁻¹². Considering uMN and uNMN separately, uMN had a good specificity but a poor sensitivity. However, four out of 11 false negatives were due to the extra-adrenal pheochromocytomas which lack phenylethanolamine- N- methyl transferase and hence predominantly secrete norepinephrine. On the contrary, uNMN had a high sensitivity with a trade-off in the specificity leading to a large number of false positives. This was especially true when the upper limit given by the assay manufacturer was used as cut-off. When the cut-off was increased to twice the upper limit, there was a significant decrease in the number of false positives.

Pheochromocytomas differ considerably in the type of bioamines produced, depending on factors like genetic mutation, adrenal/extra-adrenal location and tumour size. Hence, it is logical to combine both uMN and uNMN, while screening for pheochromocytomas. In our study, considering elevation of either uMN or uNMN above twice the manufacturer's upper limit,

Table I. Clinical and biological profile of the patients groups

Characteristic	Pheochromocytoma		No-pheochromocytoma group	
	Adrenal (n=16)	Extra adrenal (n=4)	EH (n=41)	Adrenal mass (n=11)
Gender (M/F)	10/6	2/2	34/7	6/5
Age (yr)	36.9 \pm 12.3	29.5 \pm 10.5	38.4 \pm 13.4	44.0 \pm 11.6
BMI (kg/m ²)	20.2 \pm 3.2	17.1 \pm 2.6	26.5 \pm 4.3 [§]	20.7 \pm 2.8
uMN (μ g/day)	461.5 (128-5640)	111 (59-305)*	153 (43-638) [§]	133 (52-543) [§]
uNMN (μ g/day)	4660 (329-10400)	4000 (2826-5360)	733 (219-2763) [§]	371 (85-825) [§]

Age and BMI are expressed in mean \pm SD. uMN and uNMN are expressed in median (range).

* P <0.05 adrenal vs. extra adrenal tumours; [§] P <0.05 pheochromocytoma vs. non pheochromocytomas (control).

[§] P <0.005 compared to all other groups. EH, essential hypertension; uMN, 24 h urinary metanephrine; uNMN, 24 h urinary normetanephrine

Table II. Performance characteristics of the test at different cut-off values

Test	Cut-off in $\mu\text{g/day}$	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
uMN	350	45	92.3	69.2	81.4
	700	35	100	100	80
uNMN	600	90	32.7	34	89.5
	1200	80	92.3	80	92.3
	2794	80	100	100	92.9
uMN + uNMN	uMN >350 or uNMN >600	100	28.8	35.1	100
	uMN >700 or uNMN >1200	95	92.3	82.6	97.9

uMN, 24 h urinary metanephrine; uNMN, 24 h urinary normetanephrine; uMN+uNMN, combined 24 h urinary fractionated metanephrines (uMN and/or uNMN positive); PPV, positive predictive value; NPV, negative predictive value

95 per cent sensitivity with a 92.3 per cent specificity could be achieved. The corresponding NPV was excellent (98%) and PPV (82.6%) was reasonable. However, the predictive values of any particular test will depend on the pretest probability of the disease being tested. The above predictive values apply to the present study population in a large referral center, where the phaeochromocytoma are diagnosed in a high proportion (27.7%). The test will not perform as well in

a secondary hospital level when done in an unselected population with very low tumor prevalence.

The predictive values of the test were analyzed in subsets of patients with different pretest probabilities. If we look at the subset of our patients presenting with hypertension and certain clinical symptoms suggestive of phaeochromocytoma, the prevalence was eight per cent. In this group the PPV was only 50 per cent but the NPV was 100 per cent. This implies that a negative test using the above cut-off value eliminates phaeochromocytoma as a diagnosis. On the other hand, among those with a positive test only 50 per cent would actually have the tumour. If we apply the above sensitivity and specificity figures to a general hypertensive population where the prevalence reported in available literature is as low as 0.5 per cent, the PPV drops to six per cent but the NPV still remains at 100 per cent. This makes this test suitable for ruling out phaeochromocytoma in the general hypertensive population with a very low pretest probability. In the subset of our patients with adrenal masses with or without hypertension, where the prevalence of phaeochromocytoma was 26 per cent, the PPV increased to 100 per cent and NPV decreased to 84.6 per cent. This suggests that in this group of patients with a high pretest probability, a cut-off value lower than the value we have selected would be appropriate.

Different studies employing different methods for measuring urinary fractionated metanephrines have reported different cut-off values with varying sensitivity and specificity. However, the problem of low specificity for uMN is a common finding in all studies^{13,14}. In 2002, Lenders *et al*¹¹ showed that uMN and pMN had similar sensitivity but uMN had lower specificity (69 vs 89%), however, they used different assays for urine and plasma. Later studies have proved that uMN and pMN can perform equally. Unger *et al*¹² reported similar

Table III. Predictive values at different prevalence rates of phaeochromocytoma

Patient subset (n)	Prevalence of cases confirmed as phaeochromocytoma (%)	PPV* (%)	NPV* (%)
Adrenal mass without hypertension (4)	0	-	100
Suspected secondary hypertension (45)	8	50	100
Adrenal mass with or without hypertension (15)	26	100	84.6
All suspected phaeochromocytoma (52)	27.7	82.6	98

PPV, positive predictive value; NPV, negative predictive value

*The predictive values are calculated for uMN + uNMN (either uMN or uNMN positive) at a cut-off of uMN >700 $\mu\text{g/day}$ or uNMN >1200 $\mu\text{g/day}$

specificity for pMN (79%) and uMN (75%), using RIA to measure the analytes in both urine and plasma. A recent study by Grouzmann *et al*¹⁵ concluded that in the absence of renal insufficiency both uMN and pMN perform equally. In our study, a higher specificity of 88 per cent was found by combining uMN+uNMN.

The low specificity with uMN is due to the large number of false positives caused by drugs, dietary constituents and inappropriate sampling. Drugs can alter metanephrine measurement by either directly interfering with the assay or by affecting the

endogenous catecholamine metabolism. Analytical interference by drugs with a similar chemical structure is common in high performance LC-electrochemical detection but not with MS¹⁶. The immunoassays for metanephrines are also shown to be free from analytical interference by the commonly used drugs (cross reactivity <3) which have structural similarity to metanephrines¹⁷. However, nonspecific/alpha 2 blockers and beta blockers can cause false positive elevation by inhibiting noradrenaline uptake in the sympathetic nerve terminals or by attenuating the feedback inhibition of its release. Selective alpha 1

Table IV. Studies done on the diagnostic utility of 24 h urinary fractionated metanephrines

Authors	Institute/Place	Subjects	Assay	Cut-off definition	Diagnostic threshold	Sensitivity (%)	Specificity (%)
Lenders <i>et al</i> ¹⁹ , 2002	Multi center study (NIH, Netherlands, Italy, Sweden)	214 PC+644 PE	HPLC	Upper reference limit	uMN-240/140*	NR	NR
					uNMN-540/310*	NR	NR
					uMN+uNMN	97	69
Perry <i>et al</i> ¹⁴ , 2007	Mayo clinic, Rochester, USA	102 PC + 404 PE + 221 NV	LC-MS/MS	Upper limit of 95% reference range derived from PE	uMN-302	56.9	95
					uNMN-732	87.3	95
					uMN+uNMN	97.1	91.1
Brain <i>et al</i> ²⁰ , 2006	University of Oxford, UK	1819 unselected referred patients including 14PC	Reverse phase HPLC	Upper limit of laboratory reference range	uMN-372/276*	NR	NR
					uNMN-659/549*	NR	NR
					uMN+uNMN	100	95
Unger <i>et al</i> ¹² , 2006	University of Essen, Germany	24 PC+ 84 PE + 42 NV	RIA	ROC	uMN-110.7	80	82.7
					uNMN-436.5	93.3	86.5
					uMN+uNMN	93.3	75
Boyle <i>et al</i> ² , 2007	University of Glasgow, USA	25PC+ 134 PE	HPLC	Upper limit of 97.5% reference range derived from PE	uMN-69.3	NR	NR
					uNMN-119.6	NR	NR
					uMN+uNMN	100	94
Present study	India	20 PC+52 PE	ELISA	Twice the upper limit of reference range given by assay manufacturer	uMN-700	35	100
					uNMN-1200	80	92.3
					uMN+uNMN	95	92.3

*Values for males/females. PC, pheochromocytoma confirmed; PE, pheochromocytoma excluded; NV, normotensive volunteers; HPLC, high performance liquid chromatography; LC/MS, liquid chromatography/mass spectrometry; RIA, radioimmuno assay; ELISA, enzyme linked immunosorbent assay; ROC, receiver operating characteristics; uMN, 24 h urinary metanephrine (µg/day); uNMN, 24 h urinary normetanephrine (µg/day); uMN+uNMN, uMN and/or uNMN positive; NR, not reported

blockers do not cause this problem. There are no recommendations on dietary restrictions for testing uMN. de Jong *et al*¹⁸ showed that a catecholamine rich diet can increase deconjugated normetanephrines upto 2 fold but not the metanephrines in plasma and urine. In our study, false positive elevations were more common with uNMN compared to uMN in patients without any drug or dietary restriction. This may indicate that exogenous factors influence uNMN more commonly than uMN. This does not disqualify uMN+uNMN as an initial screening test.

There is no universally accepted threshold for uMN and uNMN which can differentiate phaeochromocytomas from patients without the disease. Table IV summarizes the results of previous studies done on urinary fractionated metanephrines. Our cut-off levels differ from the previous studies indicating that the assay used and the reference population influence the clinical cut-off. Our study confirms the previous findings that the upper limit derived by studying normotensive healthy controls is of insufficient discriminatory value. It would be preferable to define the cut-off using a group of subjects suspected to have phaeochromocytoma in whom the diagnosis was excluded.

The major strength of our study was inclusion of a clinically relevant reference population and histopathologically proven phaeochromocytomas cases. The limitation of the study was that the exclusion of phaeochromocytoma in our study was done by imaging. Another limitation was that the adequacy of urine collection was not assessed by concurrent urine creatinine excretion.

In conclusion, urinary metanephrines measured by ELISA have adequate specificity to be used as an initial screening test for ruling out phaeochromocytoma. However, one cannot use the upper limit stated by the manufacturer derived from normotensive subjects as the cut-off, as there are many false positives. Increasing the cut-off to twice this upper limit improves the specificity and negative predictive value, to the extent that it can be used for ruling out phaeochromocytoma in a hypertensive population. Each hospital needs to define the cut-off by using its own assay and by choosing a proper control population. In patients with adrenal or extra-adrenal mass with hypertension, even milder elevations of urinary metanephrines may suggest the presence of phaeochromocytoma.

References

1. Eisenhofer G, Lenders JW, Pacak K. Choice of biochemical test for diagnosis of pheochromocytoma: validation of plasma metanephrines. *Curr Hypertens Rep* 2002; 4 : 250-5.
2. Boyle JG, Davidson DF, Perry CG, Connell JM. Comparison of diagnostic accuracy of urinary free metanephrines, vanillyl mandelic Acid, and catecholamines and plasma catecholamines for diagnosis of pheochromocytoma. *J Clin Endocrinol Metab* 2007; 92 : 4602-8.
3. Eisenhofer G, Huynh TT, Hiroi M, Pacak K. Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. *Rev Endocr Metab Disord* 2001; 2 : 297-311.
4. Eisenhofer G. Free or total metanephrines for diagnosis of pheochromocytoma: what is the difference? *Clin Chem* 2001; 47 : 988-9.
5. Sawka AM, Prebtani AP, Thabane L, Gafni A, Levine M, Young WF Jr. A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma. *BMC Endocr Disord* 2004; 4 : 2.
6. Unger N, Hinrichs J, Deutschbein T, Schmidt H, Walz MK, Mann K, Petersenn S. Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal mass. *Exp Clin Endocrinol Diabetes* 2012; 120 : 494.
7. Sarathi V, Pandit R, Patil VK, Lia AR, Bandgar TR, Shah NS. Performance of plasma fractionated free metanephrines by enzyme immunoassay in the diagnosis of pheochromocytoma and paraganglioma in children. *Endocr Pract* 2012; 18 : 694.
8. Procopiou M, Finney H, Akker SA, Chew SL, Drake WM, Burrin J, Grossman AB. Evaluation of an enzyme immunoassay for plasma-free metanephrines in the diagnosis of catecholamine-secreting tumors. *Eur J Endocrinol* 2009; 161 : 131.
9. Unger N, Deutschbein T, Walz MK, Mann K, Petersenn S. The value of immunoassays for metanephrines in the biochemical diagnosis of pheochromocytomas. *Horm Metab Res* 2009; 41 : 676-9.
10. Singh RJ. Advances in metanephrine testing for the diagnosis of pheochromocytoma. *Clin Lab Med* 2004; 24 : 85-103.
11. Lenders JW, Pacak K, Eisenhofer G. New advances in the biochemical diagnosis of pheochromocytoma: moving beyond catecholamines. *Ann N Y Acad Sci* 2002; 970 : 29-40.
12. Unger N, Pitt C, Schmidt IL, Walz MK, Schmid KW, Philipp T, *et al*. Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. *Eur J Endocrinol* 2006; 154 : 409-17.
13. Perry CG, Sawka AM, Singh R, Thabane L, Bajnarek J, Young WF Jr. The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma. *Clin Endocrinol (Oxf)* 2007; 66 : 703.
14. Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared

- with the combination of 24-hour urinary metanephrines and catecholamines. *J Clin Endocrinol Metab* 2003; 88 : 553.
15. Grouzmann E, Drouard-Troalen L, Baudin E, Plouin PF, Muller B, Grand D, *et al*. Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma. *Eur J Endocrinol* 2010; 162 : 951-60.
 16. Whiting MJ, Doogue MP. Advances in Biochemical Screening for Pheochromocytoma using Biogenic Amines. *Clin Biochem Rev* 2009; 30 : 3-17.
 17. Wassail J, Reed P, Kane J, Weinkove C. Freedom from drug interference in new immunoassays for urinary catecholamines and metanephrines. *Clin Chem* 1999; 45 : 2216-23.
 18. de Jong WH, Eisenhofer G, Post WJ, Muskiet FA, de Vries EG, Kema IP. Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors. *J Clin Endocrinol Metab* 2009; 94 : 2841-9.
 19. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, *et al*. Biochemical diagnosis of pheochromocytoma: which test is best? *JAMA* 2002; 287 : 1427-34.
 20. Brain KL, Kay J, Shine B. Measurement of urinary metanephrines to screen for pheochromocytoma in an unselected hospital referral population. *Clin Chem* 2006; 52 : 2060-4.

Reprint requests: Dr Simon Rajaratnam, Professor, Department of Endocrinology, Diabetes & Metabolism
Christian Medical College, Ida Scudder Road, Vellore 632 004, India
e-mail- simonrajaratnam@yahoo.com